Terri A. Sewell

Sold 2026-03-25, filed 2026-04-21 (27-day lag). Post-trade excess return vs SPY: -25.03%. The magnitude of underperformance is significant — a -25% alpha gap suggests the sale was ahead of real negative price discovery in healthcare equipment. With the trade now stale (filed April, no new disclosures), monitor for stabilization before fading the short thesis or entering a mean-reversion long on technical support.

Sold 2026-03-25 in the $15,001–$50,000 range — the larger of the two disclosed sales. Filed 2026-04-21 (27-day lag). Post-trade excess return vs SPY: -17.73%. Consumer discretionary luxury/accessible luxury names like TPR are sensitive to consumer spending compression, tariff pass-through on imported goods, and retail margin pressure. The sale size relative to GEHC suggests higher conviction on this name. The SEC Form 3/4 activity on 2026-04-06 adds an insider disclosure layer worth tracking.

Residual short thesis only. If GEHC has not mean-reverted and macro healthcare headwinds persist (reimbursement cuts, medtech tariffs), the -25.03% excess return gap may continue. However, conviction is low because the trade is outside the 30-day actionable window and the original sale amount was only $1,001–$15,000 — the smallest disclosed bracket, suggesting limited insider sizing.

If currently long TPR in a consumer book, the Sewell sale signal — combined with -17.73% excess return post-disclosure — supports a trim or full reduction on any remaining position. The signal is 57+ days stale from trade date but the underperformance has been realized. New entry on the short side requires a fresh catalyst, not a recycled disclosure.